67-kDa laminin receptor increases cGMP to induce cancer-selective apoptosis

Journal of Clinical Investigation

Volumn 123, Issue 2, 2013, Pages 787-799

  Kumazoe, Motofumi ^a   Sugihara, Kaori ^a   Tsukamoto, Shuntaro ^a   Huang, Yuhui ^a   Tsurudome, Yukari ^a   Suzuki, Takashi ^a   Suemasu, Yumi ^a   Ueda, Naoki ^a   Yamashita, Shuya ^a   Kim, Yoonhee ^a   Yamada, Koji ^a   Tachibana, Hirofumi ^a,b  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

67 KDA LAMININ RECEPTOR; CYCLIC GMP; EPIGALLOCATECHIN GALLATE; LAMININ BINDING PROTEIN; PHOSPHODIESTERASE V; PROTEIN KINASE C ALPHA; SPHINGOMYELIN PHOSPHODIESTERASE; UNCLASSIFIED DRUG; VARDENAFIL;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MULTIPLE CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

ANIMALS; APOPTOSIS; CASPASES; CATECHIN; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIC GMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; FEMALE; HUMANS; IMIDAZOLES; MALE; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE; MICE, INBRED BALB C; MOLECULAR WEIGHT; MULTIPLE MYELOMA; NEOPLASMS; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; RECEPTORS, LAMININ; SIGNAL TRANSDUCTION; SULFONES; TRIAZINES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84873330378     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI64768     Document Type: Article

References (44)

1. Carroll M, et al. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood. 1997;90(12):4947-4952.
2. Goldenberg MM. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther. 1999;21(2):309-318.
3. De Thé H, Lavau C, Marchio A, Chomienne C, Degos L, Dejean A. The PML-RAR alpha fusion mRNA generated by the t (15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell. 1991;66(4):675-684.
4. Li D, et al. 67-kDa laminin receptor in human bile duct carcinoma. Eur Surg Res. 2009;42(3):168-173.
5. Sanjuan X, et al. Overexpression of the 67-kD laminin receptor correlates with tumor progression in human colorectal carcinoma. J Pathol. 1996;179(4):376-380.
6. Al-Saleh W, Delvenne P, Van Den Brule FA, Menard S, Boniver J, Castronovo V. Expression of the 67 KD laminin receptor in human cervical preneoplastic and neoplastic squamous epithelial lesions: an immunohistochemical study. J Pathol. 1997;181(3):287-293.
7. Viacava P, Naccarato AG, Collecchi P, Ménard S, Castronovo V, Bevilacqua G. The spectrum of 67-kD laminin receptor expression in breast carcinoma progression. J Pathol. 1997;182(1):36-44.
8. Scheiman J, Tseng JC, Zheng Y, Meruelo D. Multiple functions of the 37/67-kd laminin receptor make it a suitable target for novel cancer gene therapy. Mol Ther. 2009;18(1):63-74.
9. Liu L, et al. Hypoxia-mediated up-regulation of MGr1-Ag/37LRP in gastric cancers occurs via hypoxia-inducible-factor 1-dependent mechanism and contributes to drug resist ance. J Int Cancer. 2009;124(7):1707-1715.
10. Chen ZP, Schell JB, Ho CT, Chen KY. Green tea epigallocatechin gallate shows a pronounced growth inhibitory effect on cancerous cells but not on their normal counterparts. Cancer Lett. 1998;129(2):173-179.
11. Shammas MA, et al. Specific killing of multiple myeloma cells by (-)-epigallocatechin-3-gallate extracted from green tea: biologic activity and therapeutic implications. Blood. 2006;108(8):2804-2810.
12. Yang CS, Wang X, Lu G, Picinich SC. Cancer prevention by tea: animal studies, molecular mechanisms and human relevance. Nat Rev. 2009;9(6):429-439.
13. Shanafelt TD, et al. Phase I trial of daily oral polyphenon E in patients with asymptomatic Rai stage 0 to II chronic lymphocytic leukemia. J Clin Oncol. 2009;27(23):3808-3814.
14. Bettuzzi S, et al. Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. Cancer Res. 2006;66(2):1234-1240.
15. McLarty J, Bigelow RL, Smith M, Elmajian D, Ankem M, Cardelli JA. Tea polyphenols decrease serum levels of prostate-specific antigen, hepatocyte growth factor, and vascular endothelial growth factor in prostate cancer patients and inhibit production of hepatocyte growth factor and vascular endothelial growth factor in vitro. Cancer Prev Res. 2009;2(7):673-682.
16. Brausi M, Rizzi F, Bettuzzi S. Chemoprevention of human prostate cancer by green tea catechins: two years later. A follow-up update. Eur Urol. 2008;54(2):472-473.
17. Tachibana H, Koga K, Fujimura Y, Yamada K. A receptor for green tea polyphenol EGCG. Nat Struct Mol Biol. 2004;11(4):380-381.
18. Umeda D, Yano S, Yamada K, Tachibana H. Green tea polyphenol epigallocatechin-3-gallate signaling pathway through 67-kDa laminin receptor. J Biol Chem. 2008;283(6):3050-3058.
19. Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol Ther. 2009;109(3):366-398.
20. Keravis T, Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments. Br J Pharmacol. 2012;165(5):1288-1305.
21. Porst H, et al. The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial. Int J Impotence Res. 2001;13(4):192-199.
22. Gloe T, Riedmayr S, Sohn HY, Pohl U. The 67-kDa laminin-binding protein is involved in shear stressdependent endothelial NO synthase expression. J Biol Chem. 1999;274(23):15996-16002.
23. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature. 1999;399(6736):601-605.
24. Arnold WP, Mittal CK, Katsuki S, Murad F. Nitric oxide activates guanylate cyclase and increases guanosine 3':5'-cyclic monophosphate levels in various tissue preparations. Proc Natl Acad Sci U S A. 1977;74(8):3203-3207.
25. Tsukamoto S, et al. Green tea polyphenol EGCG induces lipid raft clustering and apoptotic cell death by activating protein kinase CΔ and acid sphingomyelinase through 67-kDa laminin receptor in multiple myeloma cells. Biochem J. 2012;443(2):525-534.
26. Gou S, et al. Establishment of clonal colony-forming assay for propagation of pancreatic cancer cells with stem cell properties. Pancreas. 2007;34(4):429-435.
27. Wen J, et al. A2B adenosine receptor contributes to penile erection via PI3K/AKT signaling cascade-mediated eNOS activation. FASEB J. 2011;25(8):2823-2830.
28. Efimova T, Eckert RL. Regulation of human involucrin promoter activity by novel protein kinase C isoforms. J Biol Chem. 2000;275(3):1601-1607.
29. Hung JH, et al. FTY720 induces apoptosis in hepatocellular carcinoma cells through activation of protein kinase CΔ signaling. Cancer Res. 2008;68(4):1204-1212.
30. Blass M, et al. Tyrosine phosphorylation of protein kinase C Δ is essential for its apoptotic effect in response to etoposide. Mol Cell Biol. 2002;22(1):182-195.
31. Cataldi A, Di GV, Rapino M, Zara S, Rana RA. Ionizing radiation induces apoptotic signal through protein kinase C delta and survival signal through Akt and cyclic-nucleotide response element-binding protein (CREB) in Jurkat T cells. Biol Bull. 2009;217(2):202-212.
32. Mizuno K, et al. The proteolytic cleavage of protein kinase C isotypes, which generates kinase and regulatory fragments, correlates with Fas-mediated and 12-O-tetradecanoyl-phorbol-13-acetate-induced apoptosis. Eur J Biochem. 1997;250(1):7-18.
33. Zhang S, et al. Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat Med. 2011;17(4):461-469.
34. Ito K, et al. PML targeting eradicates quiescent leukaemia-initiating cells. Nature. 2008;453(7198):1072-1078.
35. Dai B, et al. Functional and molecular interactions between ERK and CHK2 in diffuse large B-cell lymphoma. Nat Commun. 2011;2:402.
36. Jaumann M, et al. cGMP-Prkg1 signaling and Pde5 inhibition shelter cochlear hair cells and hearing function. Nat Med. 2012;18(2):252-259.
37. Lambert JD, Kennett MJ, Sang S, Reuhl KR, Ju J, Yang CS. Hepatotoxicity of high oral dose (-)-epigallocatechin-3-gallate in mice. Food Chem Toxicol. 2010;48(1):409-416.
38. Hotston MR, et al. Homocysteine and copper interact to promote type 5 phosphodiesterase expression in rabbit cavernosal smooth muscle cells. Asian J Androl. 2008;10(6):905-913.
39. Hotston MR, et al. Sildenafil inhibits the up-regulation of phosphodiesterase type 5 elicited with nicotine and tumour necrosis factor-alpha in cavernosal vascular smooth muscle cells: mediation by superoxide. BJU Int. 2007;99(3):612-618.
40. Adachi S, et al. The inhibitory effect of (-)-epigallocatechin gallate on activation of the epidermal growth factor receptor is associated with altered lipid order in HT29 colon cancer cells. Cancer Res. 2007;67(13):6493-6501.
41. Li M, et al. Direct inhibition of insulin-like growth factor-I receptor kinase activity by (-)-epigallocatechin-3-gallate regulates cell transformation. Cancer Epidemiol Biomarkers Prev. 2007;16(3):598-605.
42. Garbisa S, et al. Tumor gelatinases and invasion inhibited by the green tea flavanol epigallocatechin-3-gallate. Cancer. 2001;91(4):822-832.
43. Maeda-Yamamoto M, Ema K, Shibuichi I. In vitro and in vivo anti-allergic effects of 'benifuuki' green tea containing O-methylated catechin and ginger extract enhancement. Cytotechnology. 2007;55(2-3):135-142.
44. Tanaka H, Yamanouchi M, Miyoshi H, Hirotsu K, Tachibana H, Takahashi T. Solid-phase synthesis of a combinatorial methylated (±)-epigallocatechin gallate library and the growth-inhibitory effects of these compounds on melanoma B16 cells. Chem Asian J. 2010;5(10):2231-2248.